Denali Therapeutics Files 8-K on Financials
Ticker: DNLI · Form: 8-K · Filed: May 6, 2025 · CIK: 1714899
| Field | Detail |
|---|---|
| Company | Denali Therapeutics Inc. (DNLI) |
| Form Type | 8-K |
| Filed Date | May 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: DNLI
TL;DR
Denali Therapeutics dropped an 8-K on May 6th covering financials. Check it out.
AI Summary
Denali Therapeutics Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 161 Oyster Point Blvd., South San Francisco, CA 94080.
Why It Matters
This filing provides investors with crucial updates on Denali Therapeutics' financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any immediate or unusual risks.
Key Players & Entities
- Denali Therapeutics Inc. (company) — Registrant
- May 6, 2025 (date) — Date of earliest event reported
- 161 Oyster Point Blvd. (address) — Principal executive offices
- South San Francisco, California (location) — Principal executive offices location
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Denali Therapeutics Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on May 6, 2025.
What is Denali Therapeutics Inc.'s principal executive office address?
Denali Therapeutics Inc.'s principal executive office is located at 161 Oyster Point Blvd., South San Francisco, California 94080.
What is the Commission File Number for Denali Therapeutics Inc.?
The Commission File Number for Denali Therapeutics Inc. is 001-38311.
What is the SIC code for Denali Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for Denali Therapeutics Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 6, 2025 regarding Denali Therapeutics Inc. (DNLI).